文献速递血液净化与透析

透析患者抗体状态、病史与SARS-CoV-2感染发生率

Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis.
PubMed 文献 · J Am Soc Nephrol · 2021-07-02

本研究在美国接受中心血透的终末期肾病患者中开展前瞻性观察,基线9.5%抗SARS-CoV-2 IgG阳性、3.6%有COVID-19病史。随访6679患者月,基线IgG阳性与任何SARS-CoV-2感染风险降低相关(IRR 0.55),与临床显现COVID-19风险更低相关(IRR 0.21)。

要点

  • 基线抗SARS-CoV-2 IgG阳性者后续任何SARS-CoV-2感染风险降低45%。
  • 基线IgG阳性者临床显现COVID-19风险降低79%。
  • 自然免疫不完整,终末期肾病患者应优先接种疫苗。

核心结论

  • 在终末期肾病患者中,自然获得的抗SARS-CoV-2 IgG阳性与后续SARS-CoV-2感染风险降低45%相关,与临床显现COVID-19风险降低79%相关。

研究设计与样本

  • 前瞻性研究,纳入美国接受中心血透的终末期肾病成人患者,共2337例符合纳入标准。
  • 暴露依据基线抗SARS-CoV-2 IgG有无及研究入组前 documented COVID-19 病史分别设定。
  • 随访6679患者月,结局为任何SARS-CoV-2感染(方案PCR检测或常规临床监测发现)和临床显现COVID-19。

主要发现

  • 基线9.5%参与者抗SARS-CoV-2 IgG阳性,3.6%有COVID-19病史。
  • 随访期间263例参与者出现任何SARS-CoV-2感染证据,其中141例为临床显现COVID-19。
  • 基线抗SARS-CoV-2 IgG阳性(对比阴性)与任何SARS-CoV-2感染风险较低相关,发生率比0.55(95%CI 0.32至0.95)。
  • 基线抗SARS-CoV-2 IgG阳性(对比阴性)与临床显现COVID-19风险较低相关,发生率比0.21(95%CI 0.07至0.67)。

临床怎么用

  • 终末期肾病患者应优先接种SARS-CoV-2疫苗,不依赖其COVID-19病史。
  • 自然免疫不完整,不应以既往感染或抗体阳性替代疫苗接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rare among individuals with few coronavirus disease 2019 (COVID-19) risk factors, the ability of naturally acquired immunity to prevent reinfection among patients with ESKD is not known. METHODS: This prospective study was conducted among adults with ESKD treated with in-center hemodialysis (ICHD) in the United States. Exposure was ascribed on the basis of the presence or absence of IgG against SARS-CoV-2 at baseline, and separately, a history of documented COVID-19 before study entry. Outcomes were assessed after an infection-free period, and were any SARS-CoV-2 infection (i.e., detected by protocolized PCR tests or during routine clinical surveillance), and clinically manifest COVID-19 (consisting of only the latter). RESULTS: Of 2337 consented participants who met study inclusion criteria, 9.5% were anti-SARS-CoV-2 IgG positive at baseline; 3.6% had a history of COVID-19. Over 6679 patient-months of follow-up, 263 participants had evidence of any SARS-CoV-2 infection, including 141 who had clinically manifest COVID-19. Presence of anti-SARS-CoV-2 IgG (versus its absence) at baseline was associated with lower risk of any SARS-CoV-2 infection (incidence rate ratio, 0.55; 95% confidence interval, 0.32 to 0.95) and clinically manifest COVID-19 0.21 (95% confidence interval, 0.07 to 0.67). CONCLUSION: Among patients with ESKD, naturally acquired anti-SARS-CoV-2 IgG positivity is associated with a 45% lower risk of subsequent SARS-CoV-2 infection, and a 79% lower risk of clinically manifest COVID-19. Because natural immunity is incomplete, patients with ESKD should be prioritized for SARS-CoV-2 vaccination, independent of their COVID-19 disease history.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cohen DE, Sibbel S, Marlowe G, et al. Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis. J Am Soc Nephrol. 2021. PMID: 34215666. doi:10.1681/ASN.2021030387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。